EUCTR2005-004061-41-IT进行中（未招募）不适用
An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 or C-1802 and a Dosing Suspension Safety Evaluation - STRATA
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Unless otherwise specified, to be eligible to participate in this study, candidates must meet the following eligibility criteria at the Screening Visit: 1. must give written informed consent and provide all authorizations required by local law 2. must be an MS subject who completed Study C-1801 or C-1802 and completed a Dosing Suspension Safety Evaluation (neurological examination and an MRI scan) -partecipated in study IMA04001(STARS) or completed 48 weeks of treatment in study 101-MS-322 in Canada-these subjects will be allowed to enter this study at start of long term treatment period 3. must be considered by the Investigator to be free of signs and symptoms suggestive of PML based on medical history, physical examination, or laboratory testing (results from the Dosing Suspension Safety Evaluation from Study C-1808 may be used) 4. must be willing to discontinue and remain free from concomitant immunosuppressive or immunomodulatory treatment (including IFN and GA) for the duration of the study. NOTE: Subjects who were found to be on placebo after being unblinded for a serious adverse event (SAE) in Study C-1801 or C-1802 are eligible to enroll in this study if they completed a Dosing Suspension Safety Evaluation, receive approval from the Biogen Idec Medical Director or the relevant Advisory Committee, meet all other inclusion criteria for this study, and are not excluded based on the exclusion criteria for this study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. considered by the Investigator to be immunocompromised, based on medical history, physical examination, or laboratory testing (results from the Dosing Suspension Safety Evaluation from Study C-1808 may be used), or due to prior immunosuppressive treatment 2. history of persistent anti-natalizumab antibodies, based upon testing from prior natalizumab studies 3. history of, or available abnormal laboratory results indicative of, any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric (including major depression), renal, and/or other major disease that would preclude the administration of a recombinant humanized antibody immunomodulating agent . The Investigator must re-review the subject`s medical fitness for participation and consider any diseases that would preclude treatment. 4. history of malignancy (subjects with basal cell carcinoma that has been completely excised prior to study entry remain eligible) 5. known history of human immunodeficiency virus infection or hematological malignancy 6. history of organ transplants 7. history of severe allergic or anaphylactic reactions or known drug hypersensitivity 8. a significant change (as determined by the Investigator) in the subject`s medical history from their previous natalizumab study 9. a clinically significant infectious illness (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days prior to the Screening Visit in Study 101-MS-321 10. discontinued natalizumab in a previous study due to allergic reaction or any other SAE considered to be related to natalizumab treatment 11. discontinued study drug in Study C-1801 or C-1802 because of an AE or due to reasons other than significant disease progression (as defined in the C-1801 and C-1802 protocols) 12. treatment with immunosuppressant medications (e.g. mitoxantrone, etc) within 3 months prior to screening 13.female subjects who are not postmenopausal for at least 1 year, surgically sterile (does not include tubal ligation), or willing to practice effective contraception (as defined by the Investigator) during the study 14. women who are breastfeeding, pregnant, or planning to become pregnant while on study are excluded until post-prgnancy/cessation of breastfeeding 15. current enrollment in any other study treatment or disease study 16. unwillingness or inability to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject`s ability to comply with the study protocol 17. other unspecified reasons that, in the opinion of the Investigator and/or Biogen Idec, make the subject unsuitable for enrollment into this study.
研究者
相似试验
进行中（未招募）
不适用
TYSABRI Long Term Re-Dosing StudyEUCTR2005-004061-41-DKBIOGEN IDEC LTD458
进行中（未招募）
不适用
TYSABRI Long Term Re-Dosing StudyMultiple sclerosis (MS)MedDRA version: 16.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2005-004061-41-HUBIOGEN IDEC LTD458
尚未招募
3 期
An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 or C-1802 and a Dosing Suspension Safety EvaluatioMultiple SclerosisACTRN12605000769684Biogen Idec900
进行中（未招募）
不适用
TYSABRI Long Term Re-Dosing StudyEUCTR2005-004061-41-DEBIOGEN IDEC LTD521
进行中（未招募）
不适用
TYSABRI Long Term Re-Dosing StudyEUCTR2005-004061-41-CZBIOGEN IDEC LTD458